Connection
Michele Fox to Middle Aged
This is a "connection" page, showing publications Michele Fox has written about Middle Aged.
|
|
Connection Strength |
|
|
|
|
|
0.452 |
|
|
|
-
Pandey S, Cottler-Fox M. ADAMTS13 Testing Methodologies and Thrombotic Thrombocytopenic Purpura (TTP): Conflicting Results Can Pose a Clinical Dilemma. Ann Clin Lab Sci. 2018 May; 48(3):373-376.
Score: 0.027
-
Pandey S, Rosenbaum E, Cottler-Fox M, Harville TO. Percent cPRA (Calculated Panel Reactive Antibody) Value Predicts Percent of Positive Platelet Crossmatches. Ann Clin Lab Sci. 2017 May; 47(3):315-318.
Score: 0.025
-
Jethava YS, Mitchell A, Epstein J, Zangari M, Yaccoby S, Tian E, Waheed S, Khan R, Papanikolaou X, Grazziutti M, Cottler-Fox M, Petty N, Steward D, Panozzo S, Bailey C, Hoering A, Crowley J, Sawyer J, Morgan G, Barlogie B, van Rhee F. Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants. Clin Cancer Res. 2017 Jun 01; 23(11):2665-2672.
Score: 0.024
-
Szmania S, Lapteva N, Garg T, Greenway A, Lingo J, Nair B, Stone K, Woods E, Khan J, Stivers J, Panozzo S, Campana D, Bellamy WT, Robbins M, Epstein J, Yaccoby S, Waheed S, Gee A, Cottler-Fox M, Rooney C, Barlogie B, van Rhee F. Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother. 2015 Jan; 38(1):24-36.
Score: 0.022
-
Abuabdou A, Rosenbaum ER, Usmani SZ, Barlogie B, Cottler-Fox M. Analysis of CD34+ cell collection using two mobilization regimens for newly diagnosed multiple myeloma patients reveals the separate impact of mobilization and collection variables. J Clin Apher. 2014 Oct; 29(5):251-5.
Score: 0.020
-
Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, Cottler-Fox M. Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia. Leukemia. 2014 Apr; 28(4):888-93.
Score: 0.019
-
Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma. Blood. 2013 Jun 06; 121(23):4753-7.
Score: 0.019
-
Muzaffar J, Usmani S, Abdallah AO, Anaissie E, Cottler-Fox M, Restrepo A. High-dose chemotherapy and autologous stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy experience. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):171-4.
Score: 0.019
-
Fassas AB, Rapoport AP, Bola?os-Meade J, Shanholtz C, Cottler-Fox M, Tricot G. Tamoxifen-based treatment induces clinically meaningful responses in multiple myeloma patients with relapsing disease after autotransplantation. Leuk Lymphoma. 2001 Nov-Dec; 42(6):1323-8.
Score: 0.017
-
Fassas AB, Buddharaju LN, Rapoport A, Cottler-Fox M, Drachenberg C, Meisenberg B, Tricot G. Fatal disseminated adenoviral infection associated with thrombotic thrombocytopenic purpura after allogeneic bone marrow transplantation. Leuk Lymphoma. 2001 Aug; 42(4):801-4.
Score: 0.017
-
Fassas AB, Bola?os-Meade J, Buddharaju LN, Rapoport A, Cottler-Fox M, Chen T, Lovchik JC, Cross A, Tricot G. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol. 2001 Jan; 112(1):237-41.
Score: 0.016
-
Fassas AB, Rapoport AP, Cottler-Fox M, Chen T, Tricot G. Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation. Br J Haematol. 2000 Nov; 111(2):662-7.
Score: 0.016
-
Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008 Dec; 143(5):641-53.
Score: 0.014
-
Tricot G, Barlogie B, Zangari M, van Rhee F, Hoering A, Szymonifka J, Cottler-Fox M. Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy. Haematologica. 2008 Nov; 93(11):1739-42.
Score: 0.014
-
Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007 Jul; 138(2):176-85.
Score: 0.013
-
Shaughnessy JD, Haessler J, van Rhee F, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007 Jun; 137(6):530-6.
Score: 0.013
-
Joseph J, Rimawi A, Mehta P, Cottler-Fox M, Sinha A, Singh BK, Pacheco R, Smith ES, Mehta JL. Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. Am J Cardiol. 2006 Mar 01; 97(5):681-4.
Score: 0.012
-
Bayer-Garner IB, Cottler-Fox M, Smoller BR. Sweet syndrome in multiple myeloma: a series of six cases. J Cutan Pathol. 2003 Apr; 30(4):261-4.
Score: 0.010
-
Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, Rapoport AP, Cottler-Fox M, Tricot G, Ruehle K, Meisenberg B. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion. 2003 Jan; 43(1):78-84.
Score: 0.009
-
Badros A, Tricot G, Toor A, Morris C, Guo C, Munshi N, Barlogie B, Cottler-Fox M. ABO mismatch may affect engraftment in multiple myeloma patients receiving nonmyeloablative conditioning. Transfusion. 2002 Feb; 42(2):205-9.
Score: 0.009
-
Yi Q, Szmania S, Freeman J, Qian J, Rosen NA, Viswamitra S, Cottler-Fox M, Barlogie B, Tricot G, van Rhee F. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010 Sep; 150(5):554-64.
Score: 0.008
-
Przepiorka D, Phillips GL, Ratanatharathorn V, Cottler-Fox M, Sehn LH, Antin JH, LeBherz D, Awwad M, Hope J, McClain JB. A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood. 1998 Dec 01; 92(11):4066-71.
Score: 0.007
-
Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 1998 Mar; 21(6):543-51.
Score: 0.007
-
Emmons RV, Doren S, Zujewski J, Cottler-Fox M, Carter CS, Hines K, O'Shaughnessy JA, Leitman SF, Greenblatt JJ, Cowan K, Dunbar CE. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood. 1997 Jun 01; 89(11):4040-6.
Score: 0.006
-
Mavroudis D, Read E, Cottler-Fox M, Couriel D, Molldrem J, Carter C, Yu M, Dunbar C, Barrett J. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood. 1996 Oct 15; 88(8):3223-9.
Score: 0.006
-
Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006 Mar 09; 354(10):1021-30.
Score: 0.006
-
Lee CK, Zangari M, Fassas A, Thertulien R, Talamo G, Badros A, Cottler-Fox M, van Rhee F, Barlogie B, Tricot G. Clonal cytogenetic changes and myeloma relapse after reduced intensity conditioning allogeneic transplantation. Bone Marrow Transplant. 2006 Mar; 37(5):511-5.
Score: 0.006
-
Gojo I, Meisenberg B, Guo C, Fassas A, Murthy A, Fenton R, Takebe N, Heyman M, Philips GL, Cottler-Fox M, Sarkodee-Adoo C, Ruehle K, French T, Tan M, Tricot G, Rapoport AP. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant. 2006 Jan; 37(1):65-72.
Score: 0.006
-
Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter C, Berenson R, Brown S, Moen RC, Greenblatt J, Stewart FM, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood. 1995 Jun 01; 85(11):3048-57.
Score: 0.006
-
Cottler-Fox M, Cipolone K, Yu M, Berenson R, O'Shaughnessy J, Dunbar C. Positive selection of CD34+ hematopoietic cells using an immunoaffinity column results in T cell-depletion equivalent to elutriation. Exp Hematol. 1995 Apr; 23(4):320-2.
Score: 0.005
-
Gojo I, Guo C, Sarkodee-Adoo C, Meisenberg B, Fassas A, Rapoport AP, Cottler-Fox M, Heyman M, Takebe N, Tricot G. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant. 2004 Jul; 34(1):69-76.
Score: 0.005
-
Lee CK, Barlogie B, Munshi N, Zangari M, Fassas A, Jacobson J, van Rhee F, Cottler-Fox M, Muwalla F, Tricot G. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J Clin Oncol. 2003 Jul 15; 21(14):2732-9.
Score: 0.005
-
Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, Zangari M, Anaissie E, Tricot G. Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003 Feb; 120(3):413-23.
Score: 0.005
-
Lee CK, Badros A, Barlogie B, Morris C, Zangari M, Fassas A, van Rhee F, Cottler-Fox M, Jacobson J, Thertulien R, Muwalla F, Mazher S, Anaissie E, Tricot G. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol. 2003 Jan; 31(1):73-80.
Score: 0.005
-
Lee CK, Barlogie B, Zangari M, Fassas A, Anaissie E, Morris C, Van Rhee F, Cottler-Fox M, Thertulien R, Muwalla F, Mazher S, Badros A, Tricot G. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant. 2002 Dec; 30(12):873-8.
Score: 0.005
-
Wilson WH, Jain V, Bryant G, Cowan KH, Carter C, Cottler-Fox M, Goldspiel B, Steinberg SM, Longo DL, Wittes RE. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol. 1992 Nov; 10(11):1712-22.
Score: 0.005
-
Spitzer TR, Cottler-Fox M, Sullivan P, Lynch M, Tefft MC, Pickle LW, Cirenza E, Cahill R, Deeg HJ, Sacher R. Continuous infusion intravenous immunoglobulin is associated with a reduced incidence of infection and achieves higher serum immunoglobulin G levels than intermittent infusion following bone marrow transplantation. Semin Hematol. 1992 Jul; 29(3 Suppl 2):123-6.
Score: 0.005
-
Badros A, Barlogie B, Siegel E, Cottler-Fox M, Zangari M, Fassas A, Morris C, Anaissie E, Van Rhee F, Tricot G. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol. 2002 Mar 01; 20(5):1295-303.
Score: 0.004
-
Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G. Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy. Bone Marrow Transplant. 2002 Feb; 29(4):303-12.
Score: 0.004
-
Cottler-Fox M, Lynch M, Pickle LW, Cahill R, Spitzer TR, Deeg HJ. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant. 1991 Jul; 8(1):27-33.
Score: 0.004
-
Badros A, Barlogie B, Morris C, Desikan R, Martin SR, Munshi N, Zangari M, Mehta J, Toor A, Cottler-Fox M, Fassas A, Anaissie E, Schichman S, Tricot G, Aniassie E. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001 May 01; 97(9):2574-9.
Score: 0.004
-
Spitzer TR, Cottler-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant. 1989 Sep; 4(5):559-65.
Score: 0.004
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|